Flagship Pioneering and Quotient Therapeutics Announce Collaboration to Identify Novel Targets for Cardiovascular and Renal Diseases
Flagship Pioneering and Quotient Form Strategic Partnership with Pfizer
Flagship Pioneering, a leading venture capital firm and life sciences innovator, and Quotient Therapeutics, a pioneer in artificial intelligence (AI)-enabled drug discovery, have announced a strategic partnership with Pfizer to identify novel targets for the treatment of cardiovascular and renal diseases.
Key Highlights of the Partnership:
- Leveraging Quotient's AI-powered discovery platform to identify novel targets
- Focus on cardiovascular and renal diseases, areas with significant unmet medical needs
- Flagship's expertise in translating scientific discoveries into therapeutic candidates
- Pfizer's deep understanding of disease biology and clinical development
Importance of the Partnership:
Cardiovascular and renal diseases are among the leading causes of morbidity and mortality worldwide. Despite significant advances in treatment, there remains a pressing need for new therapies to improve patient outcomes.
By combining Quotient's AI capabilities with Flagship's venture capital expertise and Pfizer's clinical development capabilities, the partnership aims to accelerate the identification and development of novel therapies for cardiovascular and renal diseases.
Quotes from Key Stakeholders:
"This partnership brings together world-class expertise in AI-enabled drug discovery, venture capital, and clinical development," said Dr. Noubar Afeyan, Founder and CEO of Flagship Pioneering. "We are excited to collaborate with Quotient and Pfizer to drive transformative innovation in the treatment of cardiovascular and renal diseases."
"Quotient's AI-powered drug discovery platform has consistently identified novel targets with high potential for therapeutic development," said Matt Gilsenan, CEO of Quotient Therapeutics. "This partnership with Flagship and Pfizer provides us with a unique opportunity to impact global health by developing new treatments for cardiovascular and renal diseases."
About Flagship Pioneering:
Flagship Pioneering is a venture capital firm that creates and invests in transformational life sciences companies. The firm has a proven track record of founding and building successful companies in the areas of healthcare, agriculture, industrial technologies, and energy.
About Quotient Therapeutics:
Quotient Therapeutics is a leader in the field of AI-enabled drug discovery. The company's AI-powered drug discovery platform has been used to discover novel targets for a wide range of diseases, including cancer, neurodegenerative diseases, and infectious diseases.
About Pfizer:
Pfizer is a global biopharmaceutical company that develops, manufactures, and markets a wide range of medicines and vaccines. The company has a leading position in the development and commercialization of innovative therapies for cardiovascular and renal diseases.
Comments